News & Media

The Australian Regenerative Medicine Institute (ARMI) had the honour of hosting the inaugural ABC Symposium in October. The symposia are part of a longer-term engagement initiative to strengthen institutional relationships between the Brazilian Biosciences National Laboratory (LNBio), University of Campinas (Unicamp, Brazil), University of Chile, Pontifical Catholic University of Chile and ARMI.

We would like to extend a very warm and friendly welcome to Dr Harald Janovjak, ARMI’s newest Group Leader. He is moving to Australia from Vienna, where he was an Associate Professor at the Institute of Science and Technology Austria (IST Austria).

A newly published paper in the prominent science journal ‘Nature Methods’ revealed that human pluripotent stem cells have distinct functional and molecular features when generated through various methods. This discovery, realised by the Australian Regenerative Medicine Institutes (ARMI) Polo Group, offers a new comprehensive study in the field of stem cell research. The findings were led by PhD student Ethan Liu and senior Postdoc Christian Nefzger.

ARMI is proud to introduce the Industry Advisory Committee.

MTPConnect, the Medical Technologies and Pharmaceuticals Industry Growth Centre, today announced it will provide a proposed $780,000 provisional funding over two years, with matched funding coming from the sector.

Dr Lusia Guthrie, of ARMI’s Industry Advisory Committee,  awarded the AusBiotech and Johnson & Johnson 2017 Industry Leadership Award. 

In an exciting opportunity, Jeannette Hallab was invited to be a member of the Australian-Lebanese Medical Association (ALMA) health delegation from Australia to Beirut in July 2017.

2016 saw yet another year of exceptional research excellence at the Australian Regenerative Medicine Institute (ARMI). The number of papers published in leading journals with an impact factor of greater than 10, more than doubled in 2016.

The year was bolstered with new opportunities to commercialise research at the Institute, with the announcement of a global hub of commercialisation at ARMI, the Centre for Commercialisation of Regenerative Medicine Australia.

The Spring 2017 of the ARMI newsletter, Regenerate, is now available for download in the 'Resources' section. Here are just some of the highlights for ARMI in the third quarter of 2017:

ReNerve is a biotechnology startup with tissue engineering technology which has been developed right here in Melbourne. The startup is working with ARMI and its unique laboratory facilities to further develop its technology.